<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00489177</url>
  </required_header>
  <id_info>
    <org_study_id>73-1726</org_study_id>
    <nct_id>NCT00489177</nct_id>
  </id_info>
  <brief_title>Optimal Programming to Improve Mechanical Indices, Symptoms and Exercise in Cardiac Resynchronization Therapy.</brief_title>
  <acronym>OPTIMISE-CRT</acronym>
  <official_title>Optimal Programming to Improve Mechanical Indices, Symptoms and Exercise in Cardiac Resynchronization Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This international study is assessing if repeat adjustment of the timing between the three&#xD;
      leads in a cardiac resynchronization therapy (CRT) defibrillator will increase the likelihood&#xD;
      of benefit (symptoms and heart function) compared to usual device programming. The hypothesis&#xD;
      is that QuickOpt facilitated serial optimization of sensed atrioventricular (sAV), paced&#xD;
      atrioventricular (pAV), and inter-ventricular (VV) timing in the initial 9 months following&#xD;
      successful CRT will increase the rate of clinical response and structural remodeling at 12&#xD;
      months compared to usual care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiac resynchronization therapy (CRT) is primarily designed to synchronize the mechanical&#xD;
      activity of the heart. While CRT is beneficial in average, a sizable proportion of patients&#xD;
      do not clearly benefit from (respond to) CRT. Whether routinely optimizing the timing between&#xD;
      the atria and ventricles (AV timing) and the timing between the left and right ventricles (VV&#xD;
      timing) will significantly increase the likelihood of patients benefiting from (responding&#xD;
      to) CRT is unknown.&#xD;
&#xD;
      The combination of simple and reliable measures of functional capacity (specific activity&#xD;
      score [SAS] and 6-minute walk distance) with echocardiographic measures of left ventricular&#xD;
      (LV) volume and ejection fraction (EF) is a practical way of defining response to CRT.&#xD;
&#xD;
      Based on surveys, most patients receiving CRT devices do not have formal optimization of AV&#xD;
      and VV timing. This is largely because the usefulness of this is questionable and significant&#xD;
      resources are required to perform detailed echo measurements.&#xD;
&#xD;
      A method for estimating optimal sensed AV (sAV), paced AV (pAV), and VV timing using&#xD;
      intra-cardiac electrograms (I-EGM) has been developed (QuickOptTM) and offers a quick, simple&#xD;
      and inexpensive means to optimize both CRT timing. However, the utility of QuickOptTM&#xD;
      optimization is unproven.&#xD;
&#xD;
      Primary hypothesis. QuickOpt facilitated serial optimization of sAV, pAV, and VV timing in&#xD;
      the initial 9 months following successful CRT will increase the rate of clinical response and&#xD;
      structural remodeling at 12 months compared to usual care. Clinical response will be defined&#xD;
      as a reduction in SAS of &gt; 1 class or a 25% or larger improvement in 6 minute hall walk&#xD;
      distance at 12 months versus baseline. Structural remodeling will be defined as a 15% or&#xD;
      greater reduction in left LV end systolic volume or ≥ 5% absolute improvement in echo-derived&#xD;
      LV EF at 12 months versus baseline.&#xD;
&#xD;
      Methods. Initially a sub-study of FREEDOM (NCT00418314). Now an independent trial.&#xD;
      Double-blind randomized comparison of serial QuickOpt optimization of sAV, pAV, and VV timing&#xD;
      (QuickOpt) versus usual care (Usual) in patients with highly symptomatic heart failure&#xD;
      undergoing CRT implantation. Stratification by etiology of LV dysfunction will be undertaken.&#xD;
      Serial optimization of sAV, pAV, and VV timing will be performed in the QuickOptTM group&#xD;
      immediately post-randomization, and at 3, 6, and 9 months post-randomization. Final outcome&#xD;
      will be assessed at 12 months post-randomization.&#xD;
&#xD;
      Statistical aspects. 450 patients (225 / group) will provide 85% power to detect a 15%&#xD;
      absolute improvement in the rate of response to CRT with QuickOptTM versus usual care. The&#xD;
      proportion of responders will be compared using a Mantel-Haenszel stratified analysis&#xD;
      adjusted for lead position (anterior versus non-anterior) and using an intention-to-treat&#xD;
      analysis.&#xD;
&#xD;
      Overview. Up to 50 sites in Canada, Europe, Asia and the United States will enroll patients&#xD;
      over 36 months. Countries presently enrolling patients include: Canada, the United States,&#xD;
      Switzerland, Italy, Belgium, Denmark, Austria, France, Spain, the United Kingdom, the&#xD;
      Netherlands, China, Hong Kong and Japan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical benefit (reduction in SAS of at least 1 class or a 25% or larger improvement in 6 minute hall walk distance) plus structural remodeling (15% or greater reduction in left LV end systolic volume or ≥ 5% absolute improvement in echo-derived LV EF)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of late (12-month) versus early (3 month) response to CRT</measure>
    <time_frame>3 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in BNP</measure>
    <time_frame>3 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inter-/intra-ventricular dysynchrony</measure>
    <time_frame>3 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">461</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>QuickOpt</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Usual care</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>A</intervention_name>
    <description>QuickOpt intra-cardiac electrogram optimization</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>B</intervention_name>
    <description>Single optimization in initial month post-implant</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. CRT-D indications and be implanted with an SJM CRT-D device with VV timing and a&#xD;
             compatible lead system.&#xD;
&#xD;
          2. Able to complete a 6-minute hall walk with the only limiting factor to be fatigue or&#xD;
             shortness of breath.&#xD;
&#xD;
          3. Geographically stable and willing to comply with follow-up.&#xD;
&#xD;
          4. Adequate echocardiographic images to measure LV end systolic volume.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Epicardial ventricular lead system.&#xD;
&#xD;
          2. Ability to walk ≥ 450 meters in 6 minutes&#xD;
&#xD;
          3. Limited intrinsic atrial activity (≤ 40 bpm).&#xD;
&#xD;
          4. Persistent or permanent AF.&#xD;
&#xD;
          5. 2° or 3° heart block.&#xD;
&#xD;
          6. Life expectancy is less than 1 year.&#xD;
&#xD;
          7. Patient is pregnant.&#xD;
&#xD;
          8. Receiving IV inotropic agents.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Derek V Exner, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://congress365.escardio.org/Arrhythmias-&amp;-Pacing?vgnextkeyword=exner#.VktzMoTHeBh</url>
    <description>European Heart Journal ( 2012 ) 33 ( Abstract Supplement ), 538</description>
  </link>
  <verification_date>November 2015</verification_date>
  <study_first_submitted>June 20, 2007</study_first_submitted>
  <study_first_submitted_qc>June 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2007</study_first_posted>
  <last_update_submitted>November 17, 2015</last_update_submitted>
  <last_update_submitted_qc>November 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Calgary</investigator_affiliation>
    <investigator_full_name>Dr. Derek Exner</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>cardiac resynchronization therapy</keyword>
  <keyword>response</keyword>
  <keyword>Defibrillators</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

